Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) – Stock analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for Stoke Therapeutics in a report issued on Tuesday, August 4th. HC Wainwright also issued estimates for Stoke Therapeutics’ Q4 2026 earnings at ($0.81) EPS, FY2026 earnings at ($3.35) EPS, FY2027 earnings at ($2.55) EPS and FY2028 earnings at ($1.78) EPS. Chardan Capital also reaffirmed its “buy” rating, while Canaccord retained a “buy” rating despite trimming its target to $58 from $60. Chardan Capital also reaffirmed its “buy” rating, while Canaccord retained a “buy” rating despite trimming its target to $58 from $60. Read MoreReceive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.